Tirzepatide
What is Tirzepatide? Tirzepatide is a revolutionary dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved for both type 2 diabetes management and chronic weight management, it has demonstrated unprecedented efficacy for weight loss and metabolic health optimization. Tirzepatide works by mimicking incretin hormones that regulate blood
Semaglutide
What is Semaglutide? Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist FDA-approved for type 2 diabetes management (as Ozempic injectable or Rybelsus oral) and chronic weight management (as Wegovy injectable or oral). In December 2025, oral Wegovy became the first oral GLP-1 approved for weight management, offering a 25mg
Retatrutide
What is Retatrutide? Retatrutide (LY3437943) is a novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Pivotal Phase III TRIUMPH-1 trial (May 2026) delivered 28.3% weight loss (70.3 lbs) at 80 weeks on 12mg, with a 104-week extension cohort reaching 30.3% (85.0 lbs). ADA 2026 data showed 60.6%
Mazdutide
What is Mazdutide ? Mazdutide (IBI362/LY3305677) is a first-in-class dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist, and a synthetic analog of oxyntomodulin. Unlike tirzepatide which targets GIP/GLP-1, mazdutide uniquely combines GLP-1’s appetite suppression with glucagon’s ability to stimulate thermogenesis and increase energy expenditure. Phase 3 trials (GLORY-1, GLORY-2) have
















